Galectin Therapeutics (GALT) to Release Earnings on Friday

Galectin Therapeutics (NASDAQ:GALT) is expected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Galectin Therapeutics Stock Performance

Shares of GALT opened at $1.68 on Friday. Galectin Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $4.27. The company has a market capitalization of $105.44 million, a PE ratio of -2.30 and a beta of 0.69. The stock has a fifty day moving average of $1.45 and a two-hundred day moving average of $1.99.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 30th. HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a report on Friday, December 27th.

Hedge Funds Weigh In On Galectin Therapeutics

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE raised its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) by 101.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,358 shares of the company’s stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned about 0.06% of Galectin Therapeutics worth $49,000 as of its most recent SEC filing. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.